Melbourne-based Everlab, an AI-powered health platform, secured a US$10 million seed round. Global growth equity firm Left Lane Capital led the investment. This funding will accelerate Everlab's international expansion and advance its proprietary AI platforms for preventive healthcare.
Everlab operates an AI preventive healthcare platform. It delivers personalized, proactive care through a tiered membership model. Members access advanced diagnostics like whole-body MRIs and comprehensive blood testing. Digital-first doctor consultations and intelligent health insights complement these services.
Accelerating AI-Powered Health Solutions
The company's full-stack clinical platform uses AI agents. These agents analyze complex health data, automate clinical summaries, and identify early risk markers. This technology streamlines physician workflows, enabling precise interventions. Everlab integrates with national pathology and radiology networks, maintaining longitudinal health records for diagnostic testing.
Everlab has processed over 1,000,000 biomarkers. One in four test results show abnormalities.
For 2.5% of members, findings revealed serious conditions, including early-stage cancers. Competitors like Prenuvo also offer advanced diagnostic services.
The investment will support Everlab's clinic network growth. It will also expand engineering and clinical teams. This funding strengthens the company's health technology infrastructure for global scale in AI preventive healthcare. Everlab aims to build an effective system for preventing disease.
